Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort

Journal of Clinical Oncology

Volumn 31, Issue 11, 2013, Pages 1428-1434

  Cooperberg, Matthew R ^a   Simko, Jeffry P ^a   Cowan, Janet E ^a   Reid, Julia E ^b   Djalilvand, Azita ^b   Bhatnagar, Satish ^b   Gutin, Alexander ^b   Lanchbury, Jerry S ^b   Swanson, Gregory P ^c   Stone, Steven ^b   Carroll, Peter R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Myriad Genetic Laboratories   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARAFFIN; PROSTATE SPECIFIC ANTIGEN; RNA;

ADULT; AGED; ARTICLE; CANCER OF THE PROSTATE RISK ASSESSMENT POST SURGICAL SCORE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CELL ASSAY; CELL CYCLE PROGRESSION GENE PANEL; CLINICAL ASSESSMENT TOOL; DISEASE ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SALVAGE THERAPY; VALIDATION PROCESS;

AGED; CELL CYCLE; CELL CYCLE PROTEINS; COHORT STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OUTCOME ASSESSMENT (HEALTH CARE); PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT;

EID: 84876080452     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.4396     Document Type: Article

References (25)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62:10-29, 2012
2. Lu-Yao GL, Albertsen PC, Moore DF, et al: Outcomes of localized prostate cancer following conservative management. JAMA 302:1202-1209, 2009
3. Wilt TJ, Brawer MK, Jones KM, et al: Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367:203-213, 2012
4. Thompson IM, Tangen CM, Paradelo J, et al: Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: Long-term followup of a randomized clinical trial. J Urol 181:956-962, 2009
5. Latini DM, Hart SL, Knight SJ, et al: The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol 178:826-831, 2007; discussion 831-832
6. Cuzick J, Swanson GP, Fisher G, et al: Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: A retrospective study. Lancet Oncol 12:245-255, 2011
7. Cuzick J, Berney DM, Fisher G, et al: Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer 106:1095-1099, 2012
8. Pepe MS, Feng Z, Janes H, et al: Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: Standards for study design. J Natl Cancer Inst 100:1432-1438, 2008
9. Cookson MS, Aus G, Burnett AL, et al: Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 177:540-545, 2007 (Pubitemid 46054056)
10. Cooperberg MR, Hilton JF, Carroll PR: The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer 117:5039-5046, 2011
11. Vickers AJ, Elkin EB: Decision curve analysis: A novel method for evaluating prediction models. Med Decis Making 26:565-574, 2006 (Pubitemid 44728772)
12. Swanson GP, Riggs M, Hermans M: Pathologic findings at radical prostatectomy: Risk factors for failure and death. Urol Oncol 25:110-114, 2007 (Pubitemid 46349747)
13. Cooperberg MR, Broering JM, Carroll PR: Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 28:1117-1123, 2010
14. Miller DC, Gruber SB, Hollenbeck BK, et al: Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst 98:1134-1141, 2006 (Pubitemid 44288788)
15. Sanda MG, Dunn RL, Michalski J, et al: Quality of life and satisfaction with outcome among prostatecancer survivors. N Engl J Med 358:1250-1261, 2008 (Pubitemid 351439226)
16. Wilson LS, Tesoro R, Elkin EP, et al: Cumulative cost pattern comparison of prostate cancer treatments. Cancer 109:518-527, 2007 (Pubitemid 46190959)
17. Bill-Axelson A, Holmberg L, Ruutu M, et al: Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 364:1708-1717, 2011
18. Cooperberg MR, Carroll PR, Klotz L: Active surveillance for prostate cancer: Progress and promise. J Clin Oncol 29:3669-3676, 2011
19. Conti SL, Dall'era M, Fradet V, et al: Pathological outcomes of candidates for active surveillance of prostate cancer. J Urol 181:1628-1633, 2009; discussion 1633-1634
20. Cooperberg MR, Cowan JE, Hilton JF, et al: Outcomes of active surveillance for men with intermediaterisk prostate cancer. J Clin Oncol 29:228-234, 2011
21. Thompson IM, Tangen CM, Klein EA: Is there a standard of care for pathologic stage T3 prostate cancer? J Clin Oncol 27:2898-2899, 2009
22. Bjartell A, Montironi R, Berney DM, et al: Tumour markers in prostate cancer II: Diagnostic and prognostic cellular biomarkers. Acta Oncol 50:76-84, 2011 (suppl 1)
23. Swanson GP, Quinn D: Using molecular markers to help predict who will fail after radical prostatectomy. Prostate Cancer 2011:290160, 2011
24. Freedland SJ, Humphreys EB, Mangold LA, et al: Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294:433-439, 2005 (Pubitemid 41124175)
25. Nguyen PL, Gu X, Lipsitz SR, et al: Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol 29:1517-1524, 2011